Eli Lilly and Company ( LLY ) has announced the approval by the European Commission (EC) for its radioactive diagnostic agent, Amyvid (florbetapir F 18 Injection),.
Amyvid is a shot in the arm for medical specialists as it helps in detecting the density of beta-amyloid neuritic plaques in victims suffering cognitive impairment for instance victims of Alzheimer's disease.
Amyvid had received the approval to be marketed in the U.S in 2012, and now Eli Lilly hopes to introduce it in certain parts of the EU in the next 3 months.
Amyvid is a good bet for the company, as it takes forward its initial objective of developing treatments for Alzheimer's disease. Amyvid promises to be a boon for physicians as it can support diagnostic methods while evaluating patients.